OUR NEW PROFILE IS: (NASDAQ: SPRC)
CHECK OUT THE INVESTOR PRESENTATION HERE
YAHOO FINANCE Has the Entire Float at Just 3.46 Million.
As of September 22, SPRC Has Roughly $7.5 Mill in Cash. The Market Cap is Less Than Half of That!!!!!
SPRC Focuses on the development of therapies to treat disorders of the central nervous system
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
__________________________
Hello Everyone,
We have an exciting situation that we want you to research immediately for Tuesday’s session.
This one is sitting under .70 right now and has a tiny float of just 3.46 Million according to Yahoo.
Pull up SPRC immediately.
*****BREAKING NEWS THIS MORNING*****
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
The Company previously announced positive interim results from the trial meeting its primary endpoints
TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the last patient enrolled in the Company’s Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation, completed its treatment.
The Company is expecting to receive the final trial results in the upcoming weeks.
On November 7, 2022, the Company announced positive interim results from the open label trial, which includes 20 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110. The interim results summarize the data from the first eight patients who completed the trial as per protocol.
At the interim analysis, the trial met its primary endpoints of safety, including non-treatment related adverse events and drop out patients from the trial; specifically, SCI-110 did not cause delirium, oversedation, hypotension or falls even in the highest dose tested (12.5MG Dronabinol+400mg PEA).
In addition, the interim analysis showed that the trial also met its secondary endpoint of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory (“CMAI”); out of the eight patients, six showed amelioration in agitation with no need to use rescue medication to control agitation. CMAI is a standard measure for measuring agitation in people with dementia.
Additionally, the interim analysis showed in the exploratory endpoints that appetite was increased in six out of the eight patients, as measured by the Edinburgh Feeding Evaluation in Dementia Scale. No effect was observed on cognitive measurements and sleep quality, as measured by the Mini Mental State Exam, and by the Alzheimer’s Disease Assessment Scale-cognitive subscale (for cognitive impairment assessments) and the Pittsburgh Sleep Quality Index (for quality of sleep assessment).
In general, the trial medication was well tolerated with no negative response to the treatment observed during the duration of the trial (32 days of treatments and seven days for follow-up after the trial drug was stopped).
The trial, titled “Phase II-a Open Label Trial to Evaluate the Safety, Tolerability and Efficacy Trend of SCI-110 in Patients with Alzheimer’s Disease and Agitation” is being conducted at The Israeli Medical Center for Alzheimer’s under the leadership of Dr. Alexander Kaplan, MD, principal investigator and board-certified geriatrician.
About SCI-110
SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol (Δ⁹-THC), and CannAmide™, the Company’s proprietary formulation of Palmitoylethanolamide.
SCI-110 is one of the innovative combinations of SciSparc’s cannabinoid-centric platform. Using its proprietary technology, SciSparc creates these combinations to augment the inherent properties of different cannabinoids, in this case, Dronabinol, enhancing their ability to bind with receptors in the endocannabinoid system. The potential result, as demonstrated in pre-clinical studies, is improved efficacy and, in turn, lower dosage requirements and reduced side effects as compared to the cannabinoid when administered alone.
About Alzheimer’s Disease
AD is an irreversible neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention, reasoning, and judgment. Neuropsychiatric symptoms such as apathy, social withdrawal, disinhibition, agitation, psychosis, insomnia, poor appetite, and wandering are also common in the mid to late stages.
SciSparc believes that the current pharmacological treatment of agitation in AD has an unsatisfactory benefit-to-risk ratio. All used drugs to treat AD are off label as evidenced by the fact that no FDA approved drug to treat agitation in AD exists. Hence, SciSparc believes the pharmacological treatment of agitation in AD is unequivocally, an unmet need.
ABOUT SciSparc
SciSparc’s proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.
Our primary platforms focus on the endocannabinoid system. The SciSparc pipeline composes both FDA – approved, and New Chemical Entities (NCEs) which we believe have strong potential to be indicated for targeted conditions, with no existing or sufficiently effective therapies.
Enhancing existing compounds with our proprietary technologies, we have developed novel therapies that demonstrate in clinical trials heightened bioavailability, significantly improved efficacy, lower dosage requirements, better safety profiles and a reduction in side effects.
CATALYSTS
- Proprietary Technology with cutting-edge drug combinations addressing large global unmet medical needs
- Two Phase 2 Assets addressing multi-billion markets and a Pending Phase 3* Clinical Trial
- Attractive valuation & well capitalized to execute 2022 objectives
- Key strategic partners, including leading universities, medical centers and KOLs
- Preparing to file Investigational New Drug (IND) application in pain
- Top-line pre-clinical SE study results in Status Epilepticus expected in the second half of 2022
SPRC appears to be staging a turnaround and has bounced significantly off it’s recent lows with several strong news announcements
Currently the company engaged in the following drug development programs based on THC and/or non-psychoactive CBD:
• SCI-110 for the treatment of Tourette Syndrome- currently starting phase
IIb clinical trial
• SCI-110 for the treatment of Alzheimer’s disease and agitation- Phase IIa
trial undergoing, positive interim results indicated meeting primary
endpoints
• SCI-210 for the treatment of Autism Spectrum Disorder (ASD)- Clinical
Trial in Children with ASD to start at the Soroka Medical Center, subject to
final approvals
• SCI-210 for the treatment of status epilepticus- The company announced
in December 2022, positive results of a non- clinical study for epilepsy
• SCI-160 for the treatment of pain- pre- clinical stage
ROBUST IP PORTFOLIO
SciSparc has built an intellectual property portfolio which currently comprises three granted U.S. patents and pending patent applications in six families, all focused on disorders of the central nervous system. Currently, our drug candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, and Pain.
Our research and development efforts are focused on creating a proprietary and unique combination of products, some available already in the market (CannAmide™), products in the accelerated regulatory path of 505 (b)(2) application (SCI-110, SCI-210) and
products that constitute a new chemical entity (SCI-160) in order to bring different products to market at different timelines and potentially enable us to generate immediate revenues for the company. augmenting FDA-approved natural and synthetic cannabinoids in combination with our proprietary compounds and technologies to create alternate therapies that potentiate the effects of cannabinoids and target the receptors implicated in modulating the central nervous system.
SCI-110, our proprietary drug candidate, containing Dronabinol (FDA approved synthetic form of THC), with the endocannabinoid palmitoylethanolamide (PEA).
Designed to stimulate cannabinoid receptors across the Central Nervous System and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC, the expected benefits of SCI-110 are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, side effects and adverse events.
This product is being developed under the accelerated regulatory path of 505 (b)(2) application focused on augmenting FDA-approved natural and synthetic cannabinoids to create alternate therapies that potentiate the effects of cannabinoids and target the receptors implicated in modulating the central nervous system.
This approach qualifies us for access to the FDA’s 505 (b)(2) regulatory strategy, created to facilitate the submission of novel drug candidates that meet specific criteria to the FDA for review. The 505 (b)(2) application provides us with several advantages as compared to a typical New Drug Application, including potential; lower risk and development costs, and a potentially expedited time to market.
Indications currently being investigated for treatment with SCI-110 include:
– Tourette Syndrome- (TS)
– Obstructive Sleep Apnea (OSA)
– Alzheimer’s Disease and Agitation
Our proprietary drug candidate containing cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA.
This product is initially being developed under the regulation of the Israeli Medical Cannabis Agency (IMCA) – the agency that leads the regularization of the medical cannabis field in Israel and is the first of its kind in the world. It is a complex, unique, innovative and original process. Conducting clinical trials and development under the regulation of the HQR ostensibly enables rapid and specific registration processes in a track that is unique to Israel.
The company intends to further develop the product for markets outside Israel as well. Indications currently being investigated for treatment with SCI-210 include
– Autism Spectrum Disorder (in clinical trials)
– Status Epilepticus – a form of seizures that are severe and sometimes fatal. This indication is currently investigated in pre-clinical settings.
SCI-160 is an innovative, proprietary synthetic CB2 receptor agonist created, among others, for the treatment of pain and is currently in pre-clinical studies. The CB2 receptor agonist used in this formulation – HU-433 – was invented and synthesized by Professor Raphael Mechoulam, Ph.D., Chairman of the SciSparc Scientific Advisory Board, and is protected under a patent granted in the U.S. and Europe.
CannAmide™ is an immediate unique palmitoylethanolamide (PEA) oral formulation for the reduction of chronic pain and inflammation. PEA is a cannabinoid mimetic lipid molecule found throughout the body, including the central nervous system. Similar to cannabinoids, PEA has been shown to have neuroprotective, anti-inflammatory, analgesic and anti-convulsant properties.
CannAmide is currently available in tablet form, with each dose containing 400mg active pharmaceutical ingredient. It has been designated a product license issuance from the Natural and Non-prescription Health Products Directorate (NNHPD) from Health Canada, for sale as a supplement within the nutraceuticals market.
THE CENTRAL NERVOUS SYSTEM
:max_bytes(150000):strip_icc()/brain_spinal_cord-57fe96b15f9b5805c26d5072.jpg)
The central nervous system (CNS) is the complex collection of nerve tissues that controls the activities of the body, comprising the brain and spinal cord. Disorders of the CNS include a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. These disorders may be the result of damage from an infection, inherited metabolic disorders, a degenerative condition, stroke, brain tumor, or arise from multiple unknown factors.
Most CNS disorders cannot be cured, and many have associated comorbidities. Symptoms can put a severe strain on the quality of life, interfering with everyday activities and functioning; they can be embarrassing, and in more extreme cases, debilitating. The best option for most patients is to control or limit the impact of the disease through a range of therapies from medical to surgical treatment.
THE ENDOCANNABINOID SYSTEM
The endocannabinoid system (ECS) is a neurotransmitter network tasked with maintaining homeostasis throughout the body. Essentially a biochemical communication system, the ECS comprises endogenous cannabinoids and receptors. These endogenous cannabinoids, or endocannabinoids, are produced by multiple cell types within the CNS.
The main ECS receptors — CB1 and CB2 — are located throughout the body; CB1 primarily within brain cells and CB2 across the CNS. These receptors have been implicated in the modulation of neuroinflammatory, neurodegenerative and psychiatric conditions, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, epilepsy, anxiety and depression.
Because the ECS acts with such precision, its interconnection with the CNS makes modulation of the ECS a therapeutic target for treating disorders of the CNS. And because cannabinoids, whether endogenous, plant based, or synthetic, impact the ECS equally, they are an obvious target for our continuing research and drug development efforts.
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a clinical trial
TEL AVIV, Israel, April 04, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted final approval from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, required to commence the Company’s Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome (“TS”).
The Trial is titled “A randomized, double-blind, placebo controlled, cross-over study to evaluate the efficacy, safety and tolerability of daily oral SCI-110 in treating adults with Tourette Syndrome”.
The first clinical site to receive approval to initiate the trial is the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, under the leadership of Prof. Tanya Gurevich, Head of Movement Disorders Unit, Department of Neurology.
The Company also intends to conduct the clinical trial in various sites including Yale Child Study Center, Yale School of Medicine, Connecticut, USA, under the leadership of Dr. Michael H. Bloch and Hannover Medical School, Hannover, Germany, under the leadership of Prof. Muller-Vahl, Department of Psychiatry. The launch of the clinical trial at Yale University is subject to approvals by the United States Food and Drug Administration and Yale University’s institutional review board and the launch of the clinical trial at Hannover Medical School is subject to approvals by the German Federal Institute for Drugs and Medical Devices.
“We are thrilled to launch our Phase IIb Clinical Trial in Israel and start enrollment of patients suffering from Tourette Syndrome. This trial is a key milestone in SciSparc’s pursuit of lower-dose, THC-based treatment that is potentially safer and more effective for patients than all the current available treatments,” said Oz Adler, Chief Executive Officer of SciSparc.
“TS is estimated to affect 0.5-1% of the world’s population, however the very few available treatments have limited efficacy and questionable safety. Based on previous results from our phase IIa trial conducted at Yale University, we believe our proprietary SCI-110 treatment has the potential to help TS patients around the world,” Adler added.
The objective of this clinical trial is to evaluate the efficacy, safety and tolerability of SciSparc’s proprietary drug candidate SCI-110 in adult patients (between 18 and 65 years of age) using daily oral treatment. The patients will be randomized in a 1:1 ratio to receive either SCI-110 or a SCI-110 matched placebo. The primary efficacy objective of the study will be to assess tic severity change using the Yale Global Tic Severity Scale, the most commonly used measure in clinical trials, as a continuous endpoint at week 12 and week 26 of the double-blind phase compared to baseline. The primary safety objective of the study will be to assess absolute and relative frequencies of serious adverse events for the entire population and separately for the SCI-110 and placebo groups.
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
Upon the closing which occurred on March 22, 2023, the purchase price was adjusted from $2.5 million and increased to approximately $3 million.
TEL AVIV, Israel, March 28, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the definitive agreements for the sale of approximately a 49% equity interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc. (the “Subsidiary”), which owns Wellution TM , a top-selling Amazon.com Marketplace brand, to Jeffs’ Brands Holdings Inc., a wholly-owned subsidiary of Jeffs’ Brands Ltd. (“Jeffs’ Brands”)(Nasdaq: JFBR), a data-driven e-commerce company operating on Amazon, for $2.5 million in cash and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital, which will be paid in five equal monthly installments beginning in May 2023 (the “Price Adjustment”), pursuant to the stock purchase agreement dated February 23, 2023 by and between Jeffs’ Brands, Jeffs’ Brands Holdings Inc. and SciSparc. As collateral for the payment in full of the Price Adjustment, SciSparc will hold back such number of shares of common stock of its Subsidiary, equal to the outstanding due amount of the Price Adjustment.
In addition, in connection with the closing, SciSparc and Jeffs’ Brands, will undertake a mutual share exchange in the amount of $288,238 of ordinary shares from each of SciSparc and Jeffs’ Brands.
The number of shares in the share exchange was calculated based on the average closing price of the relevant company’s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, SciSparc will acquire 247,415 ordinary shares of Jeffs’ Brands and Jeffs’ Brands will acquire 360,297 ordinary shares of SciSparc having an aggregate value of $288,238, which was adjusted from $300,000 according to the 4.99% ownership limit included in the definitive agreements (the “Exchange Shares”). Following the closing of the transaction which included an equity conversion of financing amounts previously provided to the Subsidiary by SciSparc, and upon satisfaction of the payment in full by Jeffs’ Brands of the Price Adjustment amount, SciSparc will hold approximately 51% of the Subsidiary.
As part of the definitive agreements, at the closing, Jeffs’ Brands and the Subsidiary entered into a consulting agreement by which Jeffs’ Brands will provide management services for Wellution for a monthly fee of $20,000; in addition, Jeffs’ Brands will receive a signing bonus of $51,000. The consulting agreement is for an undefined period and may be terminated by either party with 30-days’ advance notice.
Wellution™ sells dozens of hemp-based, top-ranked products, including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Wellution™ offers eight variations of natural hemp candy supplements under two parent Amazon Standard Identification Numbers (“ASIN”) on Amazon that are differentiated by their hemp oil potency. The leading parent ASIN, that was launched in 2019, has received over 26,500 reviews and is consistently ranked as the #1 best seller in the category. In total, the brand has approximately 40,000 product reviews, most of which are 4 and 5-star reviews.
Mr. Oz Adler, the Chief Executive Officer and the Chief Financial Officer of the Company, is the Chairman of the board of directors of Jeffs’ Brands. The Chairman of the Company, Mr. Amitay Weiss, and Mr. Moshe Revach are members of the board of directors of both SciSparc and Jeffs’ Brands.
Neither the Subsidiary’s shares nor the Exchange Shares have been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any states’ securities laws and may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.
NEWS
-
GlobeNewswire•6 days ago
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
The application refers to a novel psychedelic-based combination of Clearmind’s MEAI and SciSparc’s Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”),
-
GlobeNewswire•6 days ago
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
The application is for a novel psychedelic-based combination, of Clearmind’s MEAI and SciSparc’s Cannamide™ Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the filing of a patent application seeking to protect its unique combin
-
GlobeNewswire•23 days ago
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a clinical trial TEL AVIV, Israel, April 04, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted final approval from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, required to commence the Company’s
-
GlobeNewswire•last month
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
Upon the closing which occurred on March 22, 2023, the purchase price was adjusted from $2.5 million and increased to approximately $3 million. TEL AVIV, Israel, March 28, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the definitive agreements for the sale of approximately a 49% equity intere
-
GlobeNewswire•2 months ago
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, March 10, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced it has received a written notice (the “Notice”) from Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule
-
GlobeNewswire•2 months ago
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
Israeli Ministry of Health granted an approval to use SCI-110 in a clinical trial at the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel TEL AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the approval of the Israeli Ministry of Health to conduct its clinical trial titled “A
-
GlobeNewswire•2 months ago
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully manufactured clinical batches of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb trial for Tourette Syndrome (“TS”). SCI-110 batches were manufactured
-
GlobeNewswire•2 months ago
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
The cannabis oil will be used as a part of the Company’s proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed an agreement with Israel’s leading and pioneer manufacturer and distributer of cannabis-based produc
-
GlobeNewswire•2 months ago
Jeffs’ Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million
The food supplements and cosmetics brand is profitable with millions of dollars in gross annual sales Tel Aviv, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (the “Company” or “Jeffs’ Brands”) (Nasdaq: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that it has entered into a definitive agreement (the “Agreement”) with SciSparc Ltd. (“SciSparc”) (Nasdaq: SPRC), to purchase from it approximately 49% of the outstanding capital stock of Sci
-
GlobeNewswire•2 months ago
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
TEL AVIV, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed a definitive agreement to sell a 49% interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc. (the “Subsidiary”), which owns WellutionTM , a top-selling Amazon.com Marketplace brand (“Wellution”), to a wholly
-
GlobeNewswire•2 months ago
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compoundsTel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on di
-
GlobeNewswire•2 months ago
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc’s PEA Tel Aviv, Israel / Vancouver, Canada, Feb. 22, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announ
-
GlobeNewswire•2 months ago
SciSparc’s Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
MitoCareX established its initial cloud-based computing infrastructure TEL AVIV, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that its MitoCareX Bio Ltd. (“MitoCareX Bio”) joint venture , which focuses on the discovery and development of potential drugs for cancer, rare diseases and ot
-
GlobeNewswire•2 months ago
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s Cannamide™ and classical psychedelics Tel Aviv, Israel / Vancouver, Canada, Feb. 15, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today
-
GlobeNewswire•2 months ago
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
Clearmind’s applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s CannAmide™ and classical psychedelics TEL AVIV, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration w
-
GlobeNewswire•3 months ago
SciSparc Announces Corporate Restructuring plan
SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest TEL AVIV, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its board of directors has resolved on pursuing a restructuring plan which involves transferring its
-
GlobeNewswire•3 months ago
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
The Company is expected to evaluate alternatives to address potential short sales issue TEL AVIV, Israel, Jan. 23, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its board of directors has decided to examine alternative measures to address concerns of illegal short sales of its ordinary shares. The Comp
-
GlobeNewswire•3 months ago
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company’s study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval by the Soroka University Medical Center (“Sor
-
GlobeNewswire•3 months ago
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind’s drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. TEL AVIV, Israel, Jan. 17, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced additional positive pre-clinical result
-
GlobeNewswire•4 months ago
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
Ethics Committee and Israeli Ministry of Health approvals already received for the Company’s study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed an agreement with the Soroka University Medical Center, in Be’er-Sheva, Israel (“So
-
GlobeNewswire•4 months ago
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
SciSparc and Clearmind’s collaboration continues to yield positive outcomes, the latest with Clearmind results for treating obesity and its related metabolic disorders TEL AVIV, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced initial positive pre-clinical results for treatment for obesity
-
GlobeNewswire•4 months ago
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
TEL AVIV, Israel, Dec. 14, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has entered into a non-binding letter of intent (“LOI”) for the sale of a 50% interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc. (the Subsidiary”), which owns WellutionTM , a top- selling Amazon.com Marketpla
-
GlobeNewswire•5 months ago
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive results from its study of SCI-210 on Status Epilepticus (“SE”), conducted at The Sheba Fund for Health Services and Research at Chaim Sheba Medical
-
GlobeNewswire•5 months ago
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), reported the receipt of a formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per sha
-
News Direct•5 months ago
Can This Company’s Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?
By Ernest Dela Aglanu, Benzinga
-
GlobeNewswire•5 months ago
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
The new line of products will be in the fields of quality health and lifestyle products such as nutritional and dietary supplements for various purposes TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced it has entered into a letter of intent (“LOI”) with Jeffs’ Brands Ltd (“Jeffs
-
GlobeNewswire•6 months ago
___________________________
TOP MANAGEMENT
Amitay Weiss
Chairman
Mr. Weiss has served as our Chief Executive Officer between August 2020 and January 2021 and on our Board of Directors since August 2020. He is founder and Chief Executive Officer of Amitay Weiss Management Ltd. Prior to forming his company, he held several positions at Bank Poalei Agudat Israel Ltd., most recently as Vice President of Business Marketing & Development. He currently chairs and serves as director on the boards of several public companies. Mr. Weiss earned his B.A. in Economics from New England College, and his M.B.A. and LL.B from Ono Academic College in Israel – a branch of the University of Manchester.
Oz Adler, CPA
Chief Executive Officer and Chief Financial Officer
Mr. Adler joined the Company in September 2017, and since April 2018 serves as the Company Chief Financial Officer .Mr. Adler has a wide variety of managerial, financial, tax and accounting experience. Prior to joining the Company, Mr. Adler was employed as a CPA at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. He currently chairs and serves as director on the boards of several private and public companies. Mr. Adler holds a B.A. in Accounting and Business Management from The College of Management, Israel.
Adi Zuloff-Shani, PhD.
Chief Technologies Officer.
Dr. Zuloff-Shani joined the Company in February 2016, bringing more than 20 years of experience as a research and development executive in the bio-tech industry and launching start-ups in the healthcare industry. Dr. Zuloff-Shani brought 2 products from bench to market and is currently leading the development of several pharmaceutical products designated to the U.S., EU and Israeli markets. Prior to joining us, Dr. Zuloff-Shani served as Vice President Development at Macrocure Ltd. (Nasdaq: MCUR) where she led all research and development activities. Dr. Zuloff-Shani earned her Ph.D. in Human Biology and Immunology from Bar-Ilan University, Israel.
Sincerely,
